FRM
NVCR icon

Fox Run Management’s NovoCure NVCR Stock Holding History

Fox Run Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
70,780
+27,791
+65% +$421K 0.18% 163
2026
Q1 		$445K Sell
42,989
-56,416
-57% -$705K 0.08% 489
2025
Q4 		$1.29M Buy
99,405
+52,587
+112% +$675K 0.2% 120
2025
Q3 		$605K Buy
46,818
+26,530
+131% +$354K 0.09% 414
2025
Q2 		$361K Buy
+20,288
New +$354K 0.06% 588
2024
Q4 		– Sell
-32,451
Closed -$507K – 1081
2024
Q3 		$507K Buy
+32,451
New +$588K 0.11% 351
2024
Q2 		– Sell
-15,809
Closed -$247K – 980
2024
Q1 		$247K Sell
15,809
-10,415
-40% -$153K 0.05% 580
2023
Q4 		$392K Buy
26,224
+6,840
+35% +$91.5K 0.1% 392
2023
Q3 		$313K Buy
+19,384
New +$559K 0.09% 428
2018
Q2 		– Sell
-10,597
Closed -$231K – 837
2018
Q1 		$231K Buy
+10,597
New +$228K 0.06% 584
2017
Q4 		– Sell
-23,200
Closed -$461K – 813
2017
Q3 		$461K Buy
23,200
+10,200
+78% +$200K 0.13% 321
2017
Q2 		$225K Buy
+13,000
New +$168K 0.08% 510

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Fox Run Management's NVCR Position: Q2 2026 in Review

Fox Run Management increased its NovoCure (NVCR) stake by 65% in Q2 2026, buying an estimated $421K and bringing the position to 70,780 shares worth $1.07M. The position accounts for 0.18% of the portfolio, ranked #163.

Fox Run Management first reported a position in NVCR in Q2 2017 and has held it in 12 quarters since. The position peaked at $1.29M in Q4 2025. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Fox Run Management held 70,780 shares of NovoCure worth $1.07M as of Q2 2026.
  • Fox Run Management bought 27,791 NovoCure shares in Q2 2026, an estimated $421K.
  • NovoCure made up 0.18% of Fox Run Management's portfolio in Q2 2026, its #163 holding.
  • Fox Run Management first reported a position in NovoCure in Q2 2017 and has held it in 12 quarters since.
  • Fox Run Management's NovoCure position peaked at $1.29M in Q4 2025.
  • 216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.